Reperfusion injury future or investigational therapies

Jump to navigation Jump to search

Reperfusion injury Microchapters

Home

Overview

Pathophysiology

Risk Factors

Natural History, Complications & Prognosis

Treatment

Medical Therapy

Future or Investigational Therapies

Reperfusion injury future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Reperfusion injury future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Reperfusion injury future or investigational therapies

CDC on Reperfusion injury future or investigational therapies

Reperfusion injury future or investigational therapies in the news

Blogs on Reperfusion injury future or investigational therapies

Directions to Hospitals Treating Reperfusion injury

Risk calculators and risk factors for Reperfusion injury future or investigational therapies

Editors-In-Chief: Anjan K. Chakrabarti, M.D. [1]; C. Michael Gibson, M.S., M.D. [2]

Overview

While there has been significant progress made in understanding repercussion injury, from molecular mechanisms to bedside clinical interventional, there are several areas that warrant further study. Some of these topics were outlined by the 2010 National Heart, Lung, and Blood Institute Workshop on Cardioprotection[1], and include:

  1. Identifying the molecular and subcellular mechanisms responsible for postconditioning, remote conditioning, and preconditioning.
  2. Determining whether the protective mechanism triggered by remote conditioning is humoral, neural, or both.
  3. Investigating whether age, obesity, and diabetes mellitus may attenuate the beneficial effects of cardioprotective strategies.
  4. Developing additional pharmacological strategies that mimic, synergize, or augment the protection exerted by conditioning protocols in conjunction with repercussion.
  5. Establishing a cardioprotective clinical trial network concurrent with the existing and complementary preclinical network (CAESAR) to test promising cardioprotective agents and strategies in patients in the setting of both acute myocardial infarction and cardiac surgery.

References

  1. Schwartz Longacre L, Kloner RA, Arai AE, Baines CP, Bolli R, Braunwald E; et al. (2011). "New horizons in cardioprotection: recommendations from the 2010 national heart, lung, and blood institute workshop". Circulation. 124 (10): 1172–9. doi:10.1161/CIRCULATIONAHA.111.032698. PMID 21900096.